REITHERA’s Post

Check this out: Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design https://lnkd.in/eVEr8ae4

After positive midstage trial, GSK moves mRNA flu vaccine to late-stage trials British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it would now progress to late-stage clinical development. The data showed that a vaccine candidate produced positive immune responses against both A and B flu strains in younger and older adults, compared with the current standard treatments, GSK said. In July, GSK bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials. GSK, one of the world's largest vaccine manufacturers, under CEO Emma Walmsley has focussed on vaccines and infectious diseases as a strategy to boost sales and counter patent expiries and declining revenue from current bestselling medicines by the end of this decade. The trial tested various mRNA formulations in older and younger adults to find effective vaccines that could offer better protection against flu strains than current vaccines. #GSK #influenzaVaccine #mRNAfluvaccine #CovidVaccines #COVID

So excited to have my paper detailing the entire SpikoGen COVID-19 vaccine development journey over the last 4 years published. It was a roller-coaster ride as our tiny team battled monumental foes and skeptics to get our protein-based COVID-19 vaccine developed, licensed and out into the community. SpikoGen was the first recombinant spike protein vaccine in the world to get licensed even ahead of Novavax and with eight million doses safely administered, the truth is now there for all to see and criticize as I know some will feel compelled (or paid) to do. Initially targeted by the Australian media (please take note Rupert Murdoch as the Australian newspaper was the biggest culprit) with fake stories saying it wasn't effective and had no published data (both complete lies) you might wonder just who was behind the false media stories targeting us. Multiple clinical trials and more than 10 peer-reviewed publications in highly reputable journals attest to both its effectiveness and safety. Robust protection against severe COVID with no myocarditis and no deaths from blood clots. Another mRNA shot anyone? A couple of big surprises were the inability to find anyone in the trials who had received SpikoGen reporting symptoms of long COVID-19 even after they had documented COVID-19 infection - 100% protection against long COVID-19 seems extraordinary. Certainly happy to hear from anyone out there who has had SpikoGen who believes they have subsequently had long COVID. The other surprise was the longevity of hybrid protection we are seeing after a single course of SpikoGen vaccine - at some point post-vaccination most individuals have had a single mild COVID-19 infection (no surprises there as no vaccine has stopped infections) but the surprise is that almost no-one has gone on to get second COVID infections more than 2 years later. This seems very different to what we anecdotally seen with mRNA vaccines where individuals I know personally report 3 and even 4 documented COVID infections despite 5 or 6 mRNA shots. Even the Pfizer CEO reported multiple COVID infections in short succession post mRNA immunization. This suggests very different immune mechanisms are operating after mRNA and protein vaccines - of course the mRNA lobbyists just don't want to know about this. This does really make me wonder about the whole IgG4 issue after mRNA and its role in inducing tolerance rather than effector function and thereby increasing rather than decreasing the risk of future variant infections - this could explain the Cleveland Clinic data showing that the risk of infection actually goes up the more mRNA doses their clinical staff had had. We still have a lot to learn but I still believe that protein-based vaccines provide the best long-term outcomes both in respect of safety and durable protection and don't myself plan to have an mRNA vaccine any time soon. This is just my personal perspective and others are of course free to make their own choices.

GSK's recent advancements in mRNA vaccine development highlight a crucial shift in their strategy to leverage cutting-edge technology to enhance public health responses to seasonal influenza. By demonstrating the potential for superior immune responses across different age groups, the company not only positions itself at the forefront of vaccine innovation but also addresses a pressing need for more effective flu vaccines. This initiative reflects a broader trend within the pharmaceutical industry, where traditional methods are increasingly being supplemented by new technological approaches, thereby fostering a more agile and robust response to infectious diseases. Additionally, GSK's commitment to integrating artificial intelligence and machine learning into its research processes indicates a forward-thinking approach that could lead to rapid improvements in vaccine design and efficacy in the near future.

💉 Inverse vaccines: a game changer for autoimmune diseases?     ❓ What are inverse vaccines?  Unlike a traditional vaccine that instructs the immune system to identify a virus or bacteria as a threat that needs to be combated, an inverse vaccine is a therapeutic vaccine and works differently, by recognizing an antigen as a friend and thereby teaching the immune system to stop attacking the body's own tissues. What benefits can inverse vaccines bring to millions of patients with autoimmune diseases?  🔹 Targeted approach  🔹 Reduced side effects 🔹 Applicability to various diseases 💪 The emergence of inverse vaccines marks a promising step in the battle against autoimmune diseases, though many challenges still need to be met to ensure the potential of this innovation.    🎯 If you are interested in this subject, feel free to read our detailed article here: https://lnkd.in/eB35Gk5z #vaccines #health #pharmaceuticals #innovation

The Biotechnology Innovations Organization (BIO) report, The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases, on January 25, 2024, found that while the current vaccine development pipeline has great breadth, it lacks depth. On February 26, during BIO’s CEO and Investor Conference in New York City, industry leaders discussed the real-world implications of the vaccine pipeline report. David Thomas, BIO’s Senior Vice President of Industry Research, began the session by reviewing the report’s findings, while Phyllis Arthur, BIO’s Senior Vice President of Infectious Disease & Emerging Science Policy, moderated the panel. “Vaccines have led to a 100% reduction in the risk of death for a host of devastating diseases,” she said back in January. “Yet many common infections don’t have any vaccines in clinical development. That needs to change. We need to pursue both scientific and policy changes that can help spur investment in these vital products.” Biotechnology Innovation Organization Phyllis Arthur David Thomas, CFA Rajeev Venkayya, MD Andrew Allen James Wassil #vaccines #vaccineswork

#Covid19 Study: #Moderna, #Pfizer, #Oxford Vaccines Linked With Slight Increase In #Heart, #Brain Disorders Covid-19 vaccines, including those from Moderna, Pfizer and Oxford, have been linked with a slight increase in heart, brain, and blood disorders, according to a new study. The Pfizer/BioNTech and Moderna Covid-19 vaccines are mRNA vaccines, while the Oxford-AstraZeneca vaccine, the formula of which was replicated by the Serum Institute of India (SII) to manufacture Covishield, is an adenovirus-vector vaccine. In the Oxford-AstraZeneca vaccine, a modified version of a chimpanzee adenovirus called ChAdOx1 is used as a vector to deliver the genetic material of SARS-CoV-2 so that it can enter the cells of a human or another host but not replicate inside. From this genetic material, cells receive information to make the spike protein of SARS-CoV-2. Read my article to know everything. https://lnkd.in/gMPgHMxt

SINOVAC BIOTECH LTD. has initiated Phase Ⅰ clinical trial of its Reassortant Rotavirus Vaccine, Live, Oral, Hexavalent (Vero Cell), and 20 people have finished enrollment on the first day. This vaccine has been approved for clinical trial in January 2024. The study has two parts: an open-label, single-arm group involving adults and children; and a randomized, double-blinded, placebo-controlled group of infants, to evaluate the safety and tolerance in participants, and immunogenicity in infants of this vaccine. The vaccine covers six rotavirus serotypes, G1, G2, G3, G4, G9, and P1A[8], and is one of the rotavirus vaccines with broad-spectrum protection that are currently marketed/under development in the world. Human rotavirus (HRV) is the most common cause of severe fatal acute gastroenteritis in children under 5 years old and the most common cause of severe diarrheal disease in infants and young children worldwide. #vaccine #ClinicalTrial https://lnkd.in/gMQ-vEpz

Excited to share our latest publication on COVID-19 therapeutics and vaccines! 🦠💉 Joshua Gini, Olumuyiwa Ariyo, ugorexeze Eze In our recent book chapter (Chapter 18), we explored the critical role of repurposed drugs and vaccines in combating the global pandemic. We delved into the evidence supporting the efficacy of medications like dexamethasone, hydroxychloroquine, and ivermectin, as well as the impact of different vaccine types (DNA, mRNA, and non-replicating viral vector). Key findings: Hydroxychloroquine and Lopinavir/ritonavir: Ineffective in treating COVID-19. Ivermectin: Promising early results, but further research was needed. Dexamethasone: Significantly reduced mortality in severe cases. Vaccines: Proven effective in curtailing the pandemic. Remember the initial confusion and craze surrounding various COVID-19 treatments? This chapter sheds light on the efficacy of these approaches. Of course!! I would vote vaccines as the best invention for outbreaks since 1796😊 But once again, what can we learn from using what we have while exploring solutions. #COVID19 #Pharmacology #Treatment #Vaccines #PublicHealth #MedicalResearch

"Many countries around the world have reported that so-called genetic vaccines, such as those using modified mRNA encoding the spike protein and lipid nanoparticles as the drug delivery system, have resulted in post-vaccination thrombosis and subsequent cardiovascular damage, as well as a wide variety of diseases involving all organs and systems, including the nervous system. In this article, based on these circumstances and the volume of evidence that has recently come to light, we call the attention of medical professionals to the various risks associated with blood transfusions using blood products derived from people who have suffered from long COVID and from genetic vaccine recipients, including those who have received mRNA vaccines, and we make proposals regarding specific tests, testing methods, and regulations to deal with these risks. We expect that this proposal will serve as a basis for discussion on how to address post-vaccination syndrome and its consequences following these genetic vaccination programs." https://lnkd.in/gZRMFDVT